Fig. 6
Oxytocin reduces ERG b-wave amplitude via OxtR and DA receptors. A Representative ERG recordings from animals with oxytocin (Oxt) injected into one eye, as compared with the recordings from the fellow eye with saline (SAL) injection. Left: normal condition; right: pre-treated with L368, 899. B Oxt has no significant effect on a-wave amplitude with light stimulation intensity at 2.65 cd·s/m2 in normal and L368, 899 pre-treated conditions. For normal condition, n = 12 mice, p = 0.1598. For L368, 899 treated condition, n = 8 mice, p = 0.6636, paired t-test. C Same as B, but for ERG b-wave amplitude. ***p < 0.001, Wilcoxon matched-pairs signed-rank test. D Effect of Oxt on b-wave relative amplitude in normal (top) and L368, 899 treated (bottom) conditions. ERG b-wave amplitudes were normalized to b-wave amplitude recorded from the eye with SAL injection and the stimulation intensity at 0.0016 cd·s/m2, labeled with the red circle. **p < 0.01, two-way ANOVA test. E Left: representative ERG recordings from one mouse with WAY267464 injected into one eye and SAL injected into the fellow eye with light stimulation intensity at 1.47 cd·s/m2 (top) and 2.65 cd·s/m2 (Bottom). Right: effect of WAY267464 on b-wave relative amplitude. n = 7 mice, **p < 0.01, two-way ANOVA test. F Left: representative ERG traces from one mouse pre-treated with SR49059 and then injected Oxt into one eye and SAL into the fellow eye. Right: effect of Oxt on ERG b-wave relative amplitude when pre-treated with SR49059. n = 9 mice, **p < 0.01, two-way ANOVA test. G–H Same as F, but for the mice pre-treated with D1 receptor antagonist—SCH23390 (G)—and D2 receptor antagonist—L741, 626 (H). n = 8 mice for SCH23390 experiment and L741, 626 experiment, separately. p > 0.05, two-way ANOVA test